Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients

EJNMMI Research

Table 4 Univariate and multivariate cox proportional hazards regression for OS

	Variables	Univariate analysis			Multivariate analysis
	Variables	P value	HR	95% CI	P value	HR	95% CI
Clinical characteristics	COO subtypes Age Gender Ann Arbor stage IPI LDH β2-MG Ferritin	0.565 0.067 0.516 0.154 0.103 0.838 0.937 0.538	0.682 3.296 1.341 3.036 2.940 1.000 1.000 1.000	0.186–2.506 1.000–9.879 0.553–3.256 0.660–13.962 0.805–10.739 0.999–1.002 1.000–1.000 1.000–1.000
Semi-quantitative parameters	ΔSUVmax_(LLR)¹ ΔTMTV¹ ΔTLG¹ ΔSUVmax_(LLR)² ΔTMTV² ΔTLG²	0.005 0.084 0.001 0.009** 0.016* 0.080	1.011 1.026 1.038 1.011 1.001 1.000	1.003–1.018 0.997–1.056 1.016–1.016 1.003–1.019 1.000–1.002 1.000–1.000	0.030* 0.015* 0.165 0.519	1.009 1.030 1.008 1.000	1.001–1.017 1.006–1.055 0.997–1.020 0.999–1.002
I-VA E-VA	CMR or non-CMR CMR or non-CMR	0.005** 0.021*	4.288 6.127	1.554–11.838 1.319–28.470

^***p < 0.001, **p < 0.01, *p < 0.05
OS overall survival, HR Hazard Ratio, CI confidence interval, COO cell of origin, IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-Microglobulin, SUVmax maximum standardized uptake value, LLR lesion-to-liver ratio calculated as SUVmax of the residual divided by SUVmax of the liver, TMTV total metabolic tumor volume, TLG total lesion glycolysis, VA visual analysis, CMR complete metabolic response, I interim, E end of treatment, 1 interim compared to baseline, 2 end of treatment compared to baseline